Kallikrein-kinin system disbalance in chronic pancreatis in combination with metabolic syndrome.

OBJECTIVE: Inroduction: Disbalance of kallikrein-kinin system, which is present in patients with chronic pancreatitis, is quite often associated with metabolic syndrome. The aim: to study and compare the status of kallicrein-kinin system in patients with chronic pancreatitis compared with patients with comorbidity of chronic pancreatitis and metabolic syndrome. PATIENTS AND METHODS: Materials and methods: All patients were divided into two groups: I group included 58 patients with chronic pancreatitis in combination with metabolic syndrome; IІ group included 32 patients with chronic pancreatitis. . Indicators of kallicrein-kinin system in blood plasma were determined by chromatographic method. Results and conclusions: Worse condition of kallicrein-kinin system was observed in patients with metabolic syndrome. Patients with chronic pancreatitis with comorbidity with metabolic syndrome established more pronounced activation of the system of general and specific proteolysis with statistically significantly higher rates of proteolytic activity of plasma, kallikrein, α1-protease inhibitor and kininase-II (p<0.05) relative to patients with chronic pancreatitis.

Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome.

OBJECTIVE: Inroduction: The most common reasons of chronic pancreatitis are alcohol abuse, biliary tract and liver diseases, stomach and duodenum, hyperlipidemia, which is often associated with metabolic syndrome. The aim: to study the effectiveness of using medicine omega-3 polyunsaturated fatty acids in standard therapy to the correction of lipids and prooxidant-antioxidant disorders in patients with chronic pancreatitis and metabolic syndrome. PATIENTS AND METHODS: Materials and methods: The study included 90 patients with chronic pancreatitis with metabolic syndrome. They were divided into two groups: I group (45 patients) received standard treatment; II group (45 patients) along with baseline therapy received medication omega-3 polyunsaturated fatty acids (Omacor) for 2 capsules (1680 mg) for one month. RESULTS: Results: After treatment the lipid blood spectrum and prooxidant-antioxidant status have improved. CONCLUSION: Conclusions: Adding to the complex therapy of patients with chronic pancreatitis and the metabolic syndrome of the medicine omega-3 polyunsaturated fatty acids helps to improve the lipid and prooxidation-antioxidant status more significantly compared with standard baseline therapy.